Suggestions
Ben Buelow
Chief Executive Officer at Ancora Biotech
Ben Buelow is the Chief Executive Officer (CEO) of 92Bio, a biotechnology company based in Hayward, California.1 He is one of the founding team members of 92Bio, which develops novel multispecific biologics for cancer treatment.2
Professional Background
Dr. Buelow has an extensive background in the biotech industry:
Previous Roles::
- Chief Medical Officer at Ancora Biotech (October 2021 - September 2022)
- Chief Medical Officer at Teneobio, Inc. (August 2016 - October 2021)
Current Position::
- CEO at 92Bio (September 2022 - Present)
Education
Dr. Buelow has a strong academic background:
- Bachelor's degree in Classics and Classical Languages, Literatures, and Linguistics from Grinnell College (1998 - 2002)
- MD/PhD in Medicine/Immunology from the University of Washington (2002 - 2011)
- Medical License in Pathology from the University of California, San Francisco (2011 - 2016)1
Entrepreneurial Experience
Before joining 92Bio, Dr. Buelow was a founder of TeneoBio, a biotech company known for its innovative antibody platform.3 His experience at TeneoBio likely contributes to his leadership at 92Bio, where the company focuses on developing best-in-class multispecific biologics for cancer treatment.2
Dr. Buelow's expertise spans clinical development, immunology, and biotechnology, making him well-suited to lead 92Bio in its mission to revolutionize antibody research and development for improved cancer treatment outcomes.
